RecruitingNot ApplicableNCT07298382

See the Impact Beem's Blue Light Therapy Has on Your Skin Health!


Sponsor

Efforia, Inc

Enrollment

100 participants

Start Date

Oct 6, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Participants will experience a rejuvenating twice-weekly light therapy journey that blends the power of blue, red, and infrared light. Each 20-minute session flows through three phases: starting with refreshing blue light to awaken and energize, then moving into soothing red light, and finishing with deeply nourishing infrared light. This unique protocol is designed to help unlock healthier-looking skin and boost your natural glow.


Eligibility

Inclusion Criteria3

  • Can read and understand English.
  • US resident.
  • Willing and able to follow the requirements of the protocol.

Exclusion Criteria6

  • Individuals with Epilepsy
  • Individuals with Photosensitivity
  • Individuals with eye conditions
  • Pregnant individuals
  • Individuals with skin sensitivity
  • Individuals taking certain light-sensitive medications

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEBlue Light Therapy

Blue Light Therapy therapy, combining blue, red, and infrared light, has been backed by studies showing improved skin health and reduced signs of aging. The medical community generally supports light therapy for its non-invasive nature and potential benefits, though results can vary. Social media buzz highlights glowing testimonials, while the general population views it as a promising skincare enhancement with minimal risks. Benefits include improved complexion and reduced acne, with risks being rare and minor, such as temporary redness. Treatment: First 5 Minutes 450nm (Blue) Second 5 Minutes 450nm (Blue) 660nm (Red) 810nm (Infrared) Final 10 Minutes 660nm (Red) 810nm (Infrared)


Locations(1)

Efforia

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07298382


Related Trials